Please enable Javascript and disable ad blockers

Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

DGAP-HV: Bayer Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 28.04.2020 in Virtuell/Leverkusen mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

DGAP-HV: Bayer Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 28.04.2020 in Virtuell/Leverkusen mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

DGAP-HV: Bayer Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 28.04.2020 in Virtuell/Leverkusen mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

DGAP-Adhoc: Carl Zeiss Meditec AG: Revenue in second quarter of 2019/20 stagnating - Further impact on business development expected for second half 2019/20 - Currently no outlook for 2019/20 possiblehttp://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG

DGAP-Adhoc: Carl Zeiss Meditec AG: Revenue in second quarter of 2019/20 stagnating - Further impact on business development expected for second half 2019/20 - Currently no outlook for 2019/20 possible

DGAP-Adhoc: Carl Zeiss Meditec AG: Revenue in second quarter of 2019/20 stagnating - Further impact on business development expected for second half 2019/20 - Currently no outlook for 2019/20 possible

0

DGAP-Adhoc: Carl Zeiss Meditec AG: Umsatz im zweiten Quartal 2019/20 stagniert - Weitere Beeinträchtigung der Geschäftsentwicklung im zweiten Halbjahr 2019/20 erwartet - Prognose für Geschäftsjahr 2019/20 derzeit nicht möglichhttp://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG

DGAP-Adhoc: Carl Zeiss Meditec AG: Umsatz im zweiten Quartal 2019/20 stagniert - Weitere Beeinträchtigung der Geschäftsentwicklung im zweiten Halbjahr 2019/20 erwartet - Prognose für Geschäftsjahr 2019/20 derzeit nicht möglich

DGAP-Adhoc: Carl Zeiss Meditec AG: Umsatz im zweiten Quartal 2019/20 stagniert - Weitere Beeinträchtigung der Geschäftsentwicklung im zweiten Halbjahr 2019/20 erwartet - Prognose für Geschäftsjahr 2019/20 derzeit nicht möglich

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL

0

DGAP-News: Fresenius Medical Care kooperiert mit anderen Dialyseanbietern zur Bekämpfung der Coronavirus-Pandemie in den USA: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png

DGAP-News: Fresenius Medical Care kooperiert mit anderen Dialyseanbietern zur Bekämpfung der Coronavirus-Pandemie in den USA

DGAP-News: Fresenius Medical Care kooperiert mit anderen Dialyseanbietern zur Bekämpfung der Coronavirus-Pandemie in den USA

0

DGAP-News: Fresenius Medical Care partners with other dialysis providers to combat coronavirus pandemic in the U.S.: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png

DGAP-News: Fresenius Medical Care partners with other dialysis providers to combat coronavirus pandemic in the U.S.

DGAP-News: Fresenius Medical Care partners with other dialysis providers to combat coronavirus pandemic in the U.S.

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0